H3B-6527 Demonstrates Tolerability in Phase I Trial for Patients With Advanced HCC
Martin E. Gutierrez, MD, director, Drug Discovery/Phase I Unit, and co-chief and medical oncologist, Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses the early findings for H3B-6527, an FGFR4 inhibitor, as a treatment of patients with hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma
Martin E. Gutierrez, MD, director, Drug Discovery/Phase I Unit, and co-chief and medical oncologist, Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses the early findings for H3B-6527, an FGFR4 inhibitor, as a treatment of patients with hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).
At the 2019 ASCO Annual Meeting, Gutierrez presented data for the first-in-human phase I trial of H3B-6527 in patients with advanced HCC or ICC. Gutierrez says that FGFR4 can enhance tumor growth in HCC and ICC and is a rational target for treatment in this patient population.
In this dose-escalation trial, 17 of the 23 patients enrolled in the dose-escalation trial had Child-Pugh A, advanced HCC and were previously treated with a tyrosine kinase inhibitor and/or immunotherapy. H3B-6527 was administered in doses from 300 mg to 1000 mg.
The adverse effects were well tolerated, says Gutierrez. There were no dose-limiting toxicities. The most common treatment-related adverse events included diarrhea, nausea, and vomiting. Based on these safety findings, 1000 mg was the recommended dose for phase II.
